Core A: Vector Core The University of Pennsylvania (Penn) Vector Core is a critical resource for investigators requiring viral-based vectors for preclinical and translational studies for the development of gene therapies for acquired and inherited disease. The main objective of the Core is to provide advanced vector technologies derived from adeno-associated viruses (AAV) in order to facilitate the translation of gene therapy research into clinical intervention. In support of this P01 entitled ?AAV Gene Therapy for Lipid Disorders?, the Core will produce and quality control research and GMP process-comparable grade AAV vectors for preclinical and IND-enabling studies focused on treatment of familial lecithin-cholesterol acyltransferase (LCAT) deficiency and homozygous familial hypercholesterolemia (hoFH). The Core will also transfer the AAV vector manufacturing technology developed at Penn to a contract manufacturing organization (CMO) to support the proposed hoFH clinical trial, as well as develop new assays for extensive characterization of the clinical AAV vector product.

Public Health Relevance

Core A: Vector Core The Vector Core is instrumental in helping the program meet the public health goals of the NHLBI by providing state-of-the-art vector technologies for basic and preclinical research in heart, lung and blood disorders. Importantly, the Core has expertise in facilitating the translation of gene therapy research into clinical intervention. In support of this P01, the Core will provide novel AAV vectors for the development of a gene therapy for the treatment of familial lecithin-cholesterol acyltransferase (LCAT) deficiency and homozygous familial hypercholesterolemia (hoFH).

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL059407-16A1
Application #
8935365
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
2000-05-15
Project End
2020-05-31
Budget Start
2015-08-01
Budget End
2016-05-31
Support Year
16
Fiscal Year
2015
Total Cost
$157,722
Indirect Cost
$59,146
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ibrahim, Salam; Somanathan, Suryanarayan; Billheimer, Jeffrey et al. (2016) Stable liver-specific expression of human IDOL in humanized mice raises plasma cholesterol. Cardiovasc Res 110:23-9
Ajufo, Ezim; Cuchel, Marina (2016) Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia. Curr Atheroscler Rep 18:22
Rashnonejad, Afrooz; Chermahini, Gholamhossein Amini; Li, Shaoyong et al. (2016) Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene. Mol Biotechnol 58:30-6
Halder, Sujata; Van Vliet, Kim; Smith, J Kennon et al. (2015) Structure of neurotropic adeno-associated virus AAVrh.8. J Struct Biol 192:21-36
Xie, Jun; Burt, Daniel Robert; Gao, Guangping (2015) Adeno-associated virus-mediated microRNA delivery and therapeutics. Semin Liver Dis 35:81-8
Bissig-Choisat, Beatrice; Wang, Lili; Legras, Xavier et al. (2015) Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nat Commun 6:7339
Wang, Lili; Bell, Peter; Somanathan, Suryanarayan et al. (2015) Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol Ther 23:1877-87
Wang, Qiang; Lock, Martin; Prongay, Andrew J et al. (2015) Identification of an adeno-associated virus binding epitope for AVB sepharose affinity resin. Mol Ther Methods Clin Dev 2:15040
Ahmed, Seemin S; Gao, Guangping (2015) Making the White Matter Matters: Progress in Understanding Canavan's Disease and Therapeutic Interventions Through Eight Decades. JIMD Rep 19:11-22
Wang, Dan; Gao, Guangping (2014) State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med 18:67-77

Showing the most recent 10 out of 140 publications